Pharma BD Deal Intelligence

GSK plc / Stiefel Laboratories

2009 · Acquisition/Merger · $3.6B · Complete

The Street Said
75
Strongly positive — critic reaction at announcement
History Says
64
Largely worked — most objectives met
CALLED IT — OFF BY 11

GSK / Stiefel Laboratories: Achieved Stated Rationale (Score: 68/100)

Full analysis, sources & comparables →

GSK acquired Stiefel Laboratories for $3.6B, world's largest independent dermatology drug company.

Did it work? Outcome assessment

GSK / Stiefel Laboratories: Achieved Stated Rationale (Score: 68/100)

Strategic verdict
Achieved Stated Rationale

Assessment window: 15yr post-close.

Key facts

Related deals — scored

DealYearValueOutcome
GSK plc / Stiefel Laboratories (this deal)2009$3.6B64
GSK plc / SmithKline Beecham2000$12.0B79
GSK plc / Pfizer Inc.2018$0.0M77
GSK plc / Novartis AG2014$16.0B76
GSK plc / Hansoh Pharmaceutical Group Co. Ltd.2023$1.7B74
GSK plc / Nuvalent, Inc.2026$10.6B70
GSK plc / Sierra Oncology Inc.2022$1.9B70

Compare all 7 side-by-side →

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2009 deals  ·  GSK plc deals  ·  Dermatology deals